Patent: 9,040,050
✉ Email this page to a colleague
Summary for Patent: 9,040,050
| Title: | Combination treatment of CD38-expressing tumors |
| Abstract: | The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent. |
| Inventor(s): | Van De Winkel Jan, Parren Paul, Graus Yvo, Oprins Judith, De Weers Michel, Van Vugt Martine, Baadsgaard Ole, Lisby Steen |
| Assignee: | GENMAB A/S |
| Application Number: | US12442808 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,040,050
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | November 16, 2015 | ⤷ Start Trial | 2027-09-26 |
| Janssen Biotech, Inc. | DARZALEX FASPRO | daratumumab and hyaluronidase-fihj | Injection | 761145 | May 01, 2020 | ⤷ Start Trial | 2027-09-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,040,050
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008037257 | ⤷ Start Trial |
| United States of America | 2024165226 | ⤷ Start Trial |
| United States of America | 2020114000 | ⤷ Start Trial |
| United States of America | 2015231235 | ⤷ Start Trial |
| United States of America | 2010092489 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
